- This is part of a $3.5 billion cost-cutting program announced in October.
- The job cuts are due to lower-than-expected sales of Pfizer’s COVID-19 vaccine and treatment.
- The company has discontinued its Pharmaceutical Sciences Small Molecule operations at the site.